Trial Profile
Phase III Study of Icotinib Treat the Patient With Brain Metastasis EGFR-mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms BRAIN
- 28 Feb 2017 Status changed from recruiting to completed.
- 22 Sep 2015 Planned End Date changed from 1 Oct 2014 to 1 May 2017 as reported by ClinicalTrials.gov record.
- 22 Sep 2015 Planned primary completion date changed from 1 Oct 2014 to 1 May 2016 as reported by ClinicalTrials.gov record.